As there is no known cure,<unk>  is a lifelong condition. Due to the high risk of death from aortic aneurysm rupture, patients should be followed closely to monitor aneurysm formation, which can then be corrected with vascular surgery. Previous research in laboratory mice has suggested that the angiotensin II receptor antagonist losartan, which appears to block TGF-beta activity, can slow or halt the formation of aortic aneurysms in Marfan syndrome. A large clinical trial sponsored by the National Institutes of Health is currently underway to explore the use of losartan to prevent aneurysms in Marfan syndrome patients. Both Marfan syndrome and<unk>  are associated with increased TGF-beta signaling in the vessel wall. Therefore, losartan also holds promise for the treatment of<unk> . In those patients in which losartan is not halting the growth of the aorta, irbesartan has been shown to work and is currently also being studied and prescribed for some patients with this condition. If an increased heart rate is present, a cardioselective beta-1 blocker, with or without losartan, is sometimes prescribed to reduce the heart rate to prevent any extra pressure on the tissue of the aorta. Likewise, strenuous physical activity is discouraged in patients, especially weight lifting and contact sports.
Loeys–Dietz syndrome
Ehlers–Danlos syndromes
Tietz syndrome
Marfan syndrome
Frank–Ter Haar syndrome
Crigler–Najjar syndrome
Letterer–Siwe disease
Wilson–Mikity syndrome